Author

SE Church

Observed names: C. Sarah, Church Sarah, Church, Sarah, Church, Sarah E, Church, Sarah E., Church, Sarah Elizabeth, S. Church, S.E. Church, Sally E. Church, Sarah Church, Sarah E Church, Sarah E. Church, Sarah Elizabeth Church, Sarah E. Church

Observed institutions: Scripps Research Institute, Inserm, Oregon Health & Science University, Cornell University, Providence Portland Medical Center, Sorbonne Université, Sorbonne Paris Cité, Centre de Recherche des Cordeliers, Zymeworks (Canada), Nanostring Technologies (United States), Laboratoire d’immunologie intégrative du cancer, Instituto Nazionale Tumori Regina Elena, Weill Cornell Medicine, Université Paris Diderot, Université Paris Descartes, Université Pierre-et-Marie-Curie

ORCID: 0000-0002-7194-4282

Observed ORCID: 0000-0002-7194-4282

OpenAlex ID: A5055807595

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

2018 · Franck Pagès, Bernhard Mlecnik, et al. · The Lancet · 2,074

Complement System Part I – Molecular Mechanisms of Activation and Regulation

2015 · Nicolas S. Merle, Sarah Elizabeth Church, et al. · Frontiers in Immunology · 1,616

PDF

Multiplex digital spatial profiling of proteins and RNA in fixed tissue

2020 · Christopher R. Merritt, Giang T. Ong, et al. · Nature Biotechnology · 1,071

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

2016 · Bernhard Mlecnik, Gabriela Bindea, et al. · Immunity · 1,033

PDF

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

2022 · Vivek Narayan, Julie S. Barber-Rotenberg, et al. · Nature Medicine · 542

PDF

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis

2016 · Bernhard Mlecnik, Gabriela Bindea, et al. · Science Translational Medicine · 473

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

2020 · Geoffrey L. Uy, Ibrahim Aldoss, et al. · Blood · 329

PDF

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

2022 · Felice Rivellese, Anna E. A. Surace, et al. · Nature Medicine · 299

PDF

The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients

2018 · Marc Van den Eynde, Bernhard Mlecnik, et al. · Cancer Cell · 281

PDF

Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1

2004 · Michael B. Zwick, Richard Jensen, et al. · Journal of Virology · 278

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival

2017 · Bernhard Mlecnik, Marc Van den Eynde, et al. · JNCI Journal of the National Cancer Institute · 250

PDF

Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia

2020 · Jayakumar Vadakekolathu, Mark D. Minden, et al. · Science Translational Medicine · 218

PDF

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

2020 · Jayakumar Vadakekolathu, Catherine Lai, et al. · Blood Advances · 156

PDF

Considerations for treatment duration in responders to immune checkpoint inhibitors

2021 · Thomas U Marron, Aideen E Ryan, et al. · Journal for ImmunoTherapy of Cancer · 137

PDF

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

2016 · Jitka Fucikova, Iva Truxova, et al. · Blood · 135

The Long Third Complementarity-Determining Region of the Heavy Chain Is Important in the Activity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5

2004 · Michael B. Zwick, H. Kiyomi Komori, et al. · Journal of Virology · 122

The Space Omics and Medical Atlas (SOMA) and international astronaut biobank

2024 · Eliah G. Overbey, JangKeun Kim, et al. · Nature · 116

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

2023 · Eugene Shenderov, Angelo M. De Marzo, et al. · Nature Medicine · 113

PDF

Tumor‐specific CD 4+ T cells maintain effector and memory tumor‐specific CD 8+ T cells

2013 · Sarah E. Church, Shawn M. Jensen, et al. · European Journal of Immunology · 111

PDF

Molecular Features of the Broadly Neutralizing Immunoglobulin G1 b12 Required for Recognition of Human Immunodeficiency Virus Type 1 gp120

2003 · Michael B. Zwick, Paul W. H. I. Parren, et al. · Journal of Virology · 108

Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer

2022 · Yong Gu Lee, Puneeth Guruprasad, et al. · Cancer Discovery · 97

Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler

2021 · Helga Bergholtz, Jodi Carter, et al. · Cancers · 97

PDF

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

2019 · Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Davide Bedognetti, et al. · Journal for ImmunoTherapy of Cancer · 89

PDF

Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse

2015 · Sarah E. Church, Jérôme Galon · Immunity · 56

PDF

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

2018 · Geoffrey L. Uy, Michael P. Rettig, et al. · Blood · 41

Works count: 166

Citation count: 10,460

H-index: 33

I10-index: 47